How to integrate early access programmes into your pharma market access strategy
Access is everything for rare disease patients, who often [...]
Medical affairs vs drug commercialisation: understanding the line between science and sales
The line between medical affairs and drug commercialisation functions [...]
How to shape your market access and real-world evidence strategy with medical science liaison insights
The actionable, real-time feedback medical science liaisons (MSL) gather [...]
How a functional service provider approach can support your clinical study
Small and mid-sized biotechs and pharma companies live and [...]
How to drive regulatory success with effective medical writing
Submitting a dossier to the EMA or MHRA is [...]
How to manage serious adverse events in early-phase clinical trials
Reporting serious adverse events (SAE) is integral to running [...]